GlassScriptPhysician profile
Archana R Narayan
NPI 1285830935
$10,927.73
in general payments reported to CMS, 2019-2025
38 companies · $2,317 in 2025
The $2,317 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $556 · 2021: $861 · 2022: $1,845 · 2023: $2,017 · 2024: $2,303 · 2025: $2,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,209 · Education: $378 · Consulting Fee: $50.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,208.89 |
| Education | $377.68 |
| Consulting Fee | $50.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,528.61 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,361.65 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,103.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,015.46 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Genzyme Corporation | $876.36 | 2019-2025 | |
| Amgen INC. | $513.36 | 2022-2025 | Tezspire |
| Pharming Healthcare, INC. | $475.62 | 2020-2025 | Ruconest |
| Genentech USA, INC. | $473.88 | 2019-2025 | Xolair |
| Octapharma USA, INC. | $426.54 | 2019-2025 | Octagam Immune Globulin (Human), Cutaquig |
| Novartis Pharmaceuticals Corporation | $411.69 | 2019-2025 | |
| Pfizer INC. | $365.46 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $356.61 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $219.85 | 2023-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $198.94 | 2023-2024 | |
| Leo Pharma INC. | $176.74 | 2025 | Adbry, Anzupgo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $169.77 | 2019-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $169.17 | 2019-2022 | |
| Genentech, INC. | $140.40 | 2022 | |
| Csl Behring | $139.89 | 2022-2025 | Hizentra, Privigen, Haegarda |
| Covis Pharma Gmbh | $117.80 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $85.40 | 2025 | Alvesco |
| Adma Biomanufacturing LLC | $72.80 | 2022-2024 | |
| Alk-Abello, INC | $69.84 | 2020-2023 | Odactra, Ragwitek, Grastek |
| Shire North American Group INC | $63.34 | 2019 | |
| Optinose US, INC. | $57.80 | 2019-2022 | |
| Abbvie INC. | $50.39 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $42.94 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $36.32 | 2021-2023 | |
| Organon LLC | $32.90 | 2025 | |
| Lilly USA, LLC | $26.06 | 2025 | Ebglyss |
| Greer Laboratories, INC. | $25.85 | 2024 | Palforzia |
| Kaleo, INC. | $22.69 | 2020 | |
| Hikma Pharmaceuticals USA | $18.46 | 2023 | Ryaltris |
| Gc Biopharma USA, INC. | $17.63 | 2025 | Alyglo |
| Incyte Corporation | $17.16 | 2022 | |
| Ionis Pharmaceuticals, INC. | $17.05 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $15.57 | 2022 | |
| Phadia US INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.